Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02156362|
Recruitment Status : Recruiting
First Posted : June 5, 2014
Last Update Posted : July 6, 2017
It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.
The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.
|Condition or disease||Intervention/treatment||Phase|
|Thyroid Cancer||Other: follow up visit||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||650 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)|
|Actual Study Start Date :||May 2012|
|Estimated Primary Completion Date :||May 2023|
|Estimated Study Completion Date :||May 2023|
Other: follow up visit
At least 1 follow up visit per year will be done and an additional visit if needed.
- Rate of Thyroid cancer evolving to refractory stage [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02156362
|Contact: Claire BOURNAUD, MDemail@example.com|
|Contact: Françoise BORSON-CHAZOT, PHD,MDfirstname.lastname@example.org|
|Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel||Recruiting|
|Bron cedex, France, 69677|
|Contact: Claire BOURNAUD, MD +33472356999 email@example.com|
|Contact: Françoise BORSON-CHAZOT, PHD,MD +33472119319 firstname.lastname@example.org|
|Principal Investigator: Claire BOURNAUD, MD|
|Principal Investigator:||Claire BOURNAUD, MD||Hospices Civils de Lyon- Centre de Médecine Nucléaire Groupement hospitalier est, 59 boulevard Pinel, 69677 Bron cedex|